KR20180100136A - 이중특이적 항체 플랫폼 - Google Patents

이중특이적 항체 플랫폼 Download PDF

Info

Publication number
KR20180100136A
KR20180100136A KR1020187020661A KR20187020661A KR20180100136A KR 20180100136 A KR20180100136 A KR 20180100136A KR 1020187020661 A KR1020187020661 A KR 1020187020661A KR 20187020661 A KR20187020661 A KR 20187020661A KR 20180100136 A KR20180100136 A KR 20180100136A
Authority
KR
South Korea
Prior art keywords
domain
polypeptide
amino acid
acid sequence
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020187020661A
Other languages
English (en)
Korean (ko)
Inventor
마틴 프레이어
Original Assignee
바이오젠 엠에이 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오젠 엠에이 인코포레이티드 filed Critical 바이오젠 엠에이 인코포레이티드
Publication of KR20180100136A publication Critical patent/KR20180100136A/ko
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020187020661A 2015-12-18 2016-12-15 이중특이적 항체 플랫폼 Abandoned KR20180100136A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562269664P 2015-12-18 2015-12-18
US62/269,664 2015-12-18
PCT/US2016/066865 WO2017106462A1 (en) 2015-12-18 2016-12-15 Bispecific antibody platform

Publications (1)

Publication Number Publication Date
KR20180100136A true KR20180100136A (ko) 2018-09-07

Family

ID=57681809

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187020661A Abandoned KR20180100136A (ko) 2015-12-18 2016-12-15 이중특이적 항체 플랫폼

Country Status (9)

Country Link
US (1) US11447575B2 (https=)
EP (1) EP3389710A1 (https=)
JP (2) JP7138046B2 (https=)
KR (1) KR20180100136A (https=)
CN (1) CN108601830B (https=)
AU (1) AU2016370821A1 (https=)
CA (1) CA3008840A1 (https=)
MA (1) MA44054A (https=)
WO (1) WO2017106462A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018037092A1 (en) * 2016-08-26 2018-03-01 Sanofi Multispecific antibodies facilitating selective light chain pairing
KR102794369B1 (ko) 2017-08-01 2025-04-15 에이비 테라퓨틱스 인코퍼레이티드 이중특이 항체 및 그의 용도
CN110028588A (zh) * 2018-01-11 2019-07-19 上海细胞治疗研究院 抗原-Fc融合蛋白及其检测阳性CAR-T细胞的应用
US20220089704A1 (en) 2018-10-29 2022-03-24 Biogen Ma Inc. Humanized and stabilized fc5 variants for enhancement of blood brain barrier transport
EP3897851A2 (en) 2018-12-17 2021-10-27 Revitope Limited Twin immune cell engager
US12463463B2 (en) 2019-01-28 2025-11-04 Ab Therapeutics, Inc. Bispecific antibodies and uses thereof
US20220227827A1 (en) * 2019-03-25 2022-07-21 Dingfu Biotarget Co., Ltd. Proteinaceous heterodimer and use thereof
US12077603B2 (en) * 2019-08-15 2024-09-03 Regeneron Pharmaceuticals, Inc. Multispecific antigen-binding molecules for cell targeting and uses thereof
US20220306760A1 (en) * 2019-08-23 2022-09-29 Igm Biosciences, Inc. Igm glycovariants
MX2022003507A (es) * 2019-09-25 2022-04-25 Univ Stuttgart Modulos de union que comprenden dominios ehd2 modificados.
WO2021139758A1 (zh) * 2020-01-09 2021-07-15 江苏恒瑞医药股份有限公司 新型多肽复合物
CN113307879A (zh) * 2020-02-27 2021-08-27 启愈生物技术(上海)有限公司 一种taa/ctla-4/il15三功能融合蛋白及其应用
CN113563473A (zh) * 2020-04-29 2021-10-29 三生国健药业（上海）股份有限公司 四价双特异性抗体、其制备方法和用途
WO2022096704A1 (en) * 2020-11-06 2022-05-12 Amgen Inc. Antigen binding domain with reduced clipping rate
CA3219388A1 (en) * 2021-05-14 2022-11-17 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Antigen-binding molecule
JP2024527977A (ja) 2021-07-27 2024-07-26 ノヴァブ， インコーポレイテッド 免疫エフェクター機能を有する操作されたｖｌｒｂ抗体
JP2025532897A (ja) * 2022-09-28 2025-10-03 ドレン バイオ， インコーポレイテッド 多重特異性抗体及びその使用方法
WO2025042806A2 (en) 2023-08-21 2025-02-27 Modernatx, Inc. C-met binding antibodies, nucleic acids encoding same, and methods of use
WO2026044055A1 (en) 2024-08-23 2026-02-26 Modernatx, Inc. Muc16 binding molecules, nucleic acids encoding same, and methods of use
WO2026075820A1 (en) 2024-10-03 2026-04-09 Modernatx, Inc. 4-1bb binding molecules, nucleic acids encoding same, and methods of use
CN121148519B (zh) * 2025-11-18 2026-02-13 西北农林科技大学 基于计算模拟辅助的双特异性抗体分子设计与优化方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090162359A1 (en) * 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
MX342034B (es) * 2011-02-28 2016-09-12 Hoffmann La Roche Proteinas monovalentes que se unen a antigenos.
WO2013012733A1 (en) * 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
WO2013156054A1 (en) * 2012-04-16 2013-10-24 Universität Stuttgart The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity
MX2014014162A (es) * 2012-05-24 2015-02-04 Hoffmann La Roche Anticuerpos multiespecificos.
CA2926853C (en) * 2013-10-18 2022-04-26 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of a vegf antagonist and an anti-ctla-4 antibody
WO2016087650A1 (en) * 2014-12-05 2016-06-09 Merck Patent Gmbh Domain-exchanged antibody
WO2017011342A1 (en) 2015-07-10 2017-01-19 Abbvie Inc. Igm-or-ige-modified binding proteins and uses thereof
WO2018037092A1 (en) * 2016-08-26 2018-03-01 Sanofi Multispecific antibodies facilitating selective light chain pairing
EP3897851A2 (en) * 2018-12-17 2021-10-27 Revitope Limited Twin immune cell engager

Also Published As

Publication number Publication date
JP2021121642A (ja) 2021-08-26
JP2019502694A (ja) 2019-01-31
CN108601830B (zh) 2023-02-03
CA3008840A1 (en) 2017-06-22
JP7138046B2 (ja) 2022-09-15
US20190048098A1 (en) 2019-02-14
AU2016370821A1 (en) 2018-07-12
EP3389710A1 (en) 2018-10-24
MA44054A (fr) 2018-10-24
WO2017106462A1 (en) 2017-06-22
US11447575B2 (en) 2022-09-20
CN108601830A (zh) 2018-09-28

Similar Documents

Publication Publication Date Title
US11447575B2 (en) Bispecific antibody platform
Schepens et al. An affinity-enhanced, broadly neutralizing heavy chain–only antibody protects against SARS-CoV-2 infection in animal models
KR102784293B1 (ko) Cd3 결합 폴리펩타이드
JP7286267B2 (ja) 修飾ｔ細胞に対する条件的活性型キメラ抗原受容体
JP2022081654A (ja) 低粘度の抗原結合タンパク質およびそれらの作製方法
BR112020000769A2 (pt) anticorpo de dupla especificidade, moléculas polipeptídicas, ácido nucleico, célula hospedeira, composição farmacêutica e método de tratamento de uma doença ou condição
JP2021137013A5 (https=)
CN111995674A (zh) 抗COVID-19病毒中和抗体mhC3及其人源化抗体与应用
CN101291692A (zh) 抗addl单克隆抗体及其应用
KR20230170121A (ko) 비통합성 바이러스 전달 시스템 및 이와 관련된 방법
KR102449406B1 (ko) 백시니아 바이러스/진핵 세포에서 폴리뉴클레오티드 라이브러리를 생산하기 위한 개선된 방법
KR20140114833A (ko) 신생아 Fc 수용체에 대해 향상된 결합을 지니는 변이체 Fc-폴리펩타이드
JP7008406B2 (ja) ポリペプチドを発現する宿主細胞を選択するための発現構築物および方法
CN101633933A (zh) 表达抗体或抗体类似物的重组克鲁维酵母菌及其构建方法与应用
KR20160035084A (ko) 진핵세포의 폴리펩티드 발현 방법 및 발현 구조체
JP2013509188A (ja) Ｓｏｒｆ構築物および複数の遺伝子発現
KR20240052854A (ko) Mhc 단백질 기반 이종 이량체를 포함하는 이중 특이적 항체
WO2017180555A1 (en) Humanized anti-rage antibody
US20220281957A1 (en) Modified human variable domains
RU2787060C1 (ru) НУКЛЕОТИДНАЯ ПОСЛЕДОВАТЕЛЬНОСТЬ, КОДИРУЮЩАЯ СЛИТЫЙ БЕЛОК, СОСТОЯЩИЙ ИЗ РАСТВОРИМОГО ВНЕКЛЕТОЧНОГО ФРАГМЕНТА ЧЕЛОВЕЧЕСКОГО Dll4 И КОНСТАНТНОЙ ЧАСТИ ТЯЖЕЛОЙ ЦЕПИ ЧЕЛОВЕЧЕСКОГО IgG4
KR101718764B1 (ko) 항체 발현용 바이시스트로닉 발현벡터 및 이를 이용한 항체의 생산 방법
WO2024182781A1 (en) Coronavirus compositions and uses thereof
HK40012343A (en) Low-viscosity antigen binding proteins and methods of making them
KR20080068040A (ko) 항-ａｄｄｌ 단일클론 항체 및 그 이용 방법
EA042409B1 (ru) Полипептиды, связывающие cd3

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180718

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20211209

Comment text: Request for Examination of Application

PC1902 Submission of document of abandonment before decision of registration